



**SANDHILLS  
CENTER**



# Intracranial hypertension stent

Clinical Policy ID: CCP.1493

Recent review date: 7/2021

Next review date: 11/2022

Policy contains: Idiopathic intracranial hypertension, pseudotumor cerebri, stent

*This policy is a Sandhills Center Clinical Coverage Policy adopted from AmeriHealth Caritas of North Carolina. These clinical policies are used to assist with making coverage determinations. Sandhills Center's clinical policies are based on guidelines from established industry sources, such as the Centers for Medicare & Medicaid Services (CMS), state regulatory agencies, the American Medical Association (AMA), medical specialty professional societies, and peer-reviewed professional literature. These clinical policies along with other sources, such as plan benefits and state and federal laws and regulatory requirements, including any state- or plan-specific definition of "medically necessary," and the specific facts of the particular situation are considered by Sandhills Center when making coverage determinations. In the event of conflict between this clinical policy and plan benefits and/or state or federal laws and/or regulatory requirements, the plan benefits and/or state and federal laws and/or regulatory requirements shall control. Sandhills Center clinical policies are for informational purposes only and not intended as medical advice or to direct treatment. Physicians and other health care providers are solely responsible for the treatment decisions for their patients. Sandhills Center's clinical policies are reflective of evidence-based medicine at the time of review. As medical science evolves, Sandhills Center will update its clinical policies as necessary. Sandhills Center clinical policies are not guarantees of payment.*

## Coverage policy

Stents for intracranial hypertension are investigational/not clinically proven and, therefore, not medically necessary.

### Limitations

No limitations were identified during the writing of this policy.

### Alternative covered services

- Medication therapy (e.g., acetazolamide).
- Shunting (insertion of tube into brain).

## Background

Idiopathic intracranial hypertension, also known as pseudotumor cerebri, is a condition marked by persistently increased intracranial pressure with no known origin. Incidence for all ages is approximately 1 in 100,000 persons, and is highest in overweight women ages 20 – 44, estimated at 19 in 100,000 (Daggubati, 2019; Wall, 2010).

Common symptoms of intracranial hypertension include headache (94%), transient visual obscurations (68%), pulse synchronous tinnitus (58%), photopsia (54%), retrobulbar pain (44%), diplopia (38%), and visual loss (30%) (Wall, 2010). The most common neurologic abnormality is papilledema, observed in 95% of cases. Other

CCP.1493

abnormalities include dizziness, nausea, reduced memory and concentration, and horizontal diplopia (Jensen, 2016). The criteria used to diagnose intracranial hypertension is essentially unchanged since 2002, and includes signs and symptoms attributable only to elevated intracranial pressure; cerebrospinal fluid opening pressure of greater than 25 centimeters H<sub>2</sub>O; normal cerebrospinal fluid composition; and no evidence after neuroimaging of mass lesion or other structural causes (Al-Mufti, 2020). Fundoscopy, optical coherence tomography, neuroimaging (often magnetic resonance imaging), and lumbar puncture with manometry are used in diagnosis (Jensen, 2016).

Multiple treatments for idiopathic intracranial hypertension exist. Experts recommend weight loss for those who are overweight. Monitoring of psychosocial issues is important, although consensus is lacking in standardized measures. The most common medical treatment is acetazolamide — a diuretic and carbonic anhydrase inhibitor — sometimes combined with other drugs (Thurtell, 2021).

Surgical treatments in cases refractory to conservative approaches include various approaches to shunting cerebrospinal fluid, optic nerve sheath fenestration, and cerebral venous sinus stents (also known as intracranial hypertension stents). No consensus on indications for stenting exists, other than that use is indicated only in patients with a pressure gradient over 8 millimeters of mercury across the stenosis and increased venous pressures in the venous sinuses near the stenosis (Thurtell, 2021).

The process of stenting includes cerebral angiography with a guide catheter through femoral artery puncture, and venography/venous manometry (under conscious sedation) through femoral vein access, with a shuttle catheter at the internal jugular vein. Venous stents, placed under general anesthesia, span 10 millimeters prestenosis and poststenosis (Daggubati, 2019).

## Findings

Two Medicare Local Coverage Determinations classify venous stenting for idiopathic intracranial hypertension as investigational. The basis for this determination is insufficient information on efficacy and the need for a large, multicenter, randomized trial (Centers for Medicare & Medicaid Services, 2020).

A consensus guideline issued by four British professional medical societies on management of idiopathic intracranial hypertension does not recommend neurovascular stenting for either visual loss or headache alone, as the role of the procedure is not established. Reasons include observed complications; lack of long-term data on efficacy and safety; and methodological limits, i.e., studies are mostly case series, not randomized, and have small sample sizes (Mollan, 2018).

A guideline from the European Headache Foundation states that while some institutions employ venous sinus stenting to treat idiopathic intracranial hypertension, “utility is debated.” This guideline also does not recommend the procedure to treat headaches in persons with the disorder (Hoffmann, 2018).

A guideline from the Royal College of Physicians states that ventriculoperitoneal shunts can be used to divert cerebrospinal fluid, and that optic nerve sheath fenestration is an alternative to treating intracranial hypertension. However, the ability of endovascular stenting to improve long-term outcomes is uncertain (Wakerley, 2020).

An article in an American Academy of Ophthalmology magazine, in which two prominent experts are interviewed, CCP.1493

cites fenestration and shunting as potential surgical options for idiopathic intracranial hypertension, but does not mention stents (Weiner, 2021).

A systematic review of 109 studies compared outcomes for various types of surgery for idiopathic intracranial hypertension. Venous sinus stenting improved papilledema, visual fields and headaches in 87.1%, 72.7% and 72.1% of patients, with failure and complication rates of 2.3% and 11.3%. Less efficacy and safety generally resulted after cerebrospinal fluid diversion (78.9%, 66.8%, 69.8%, 9.4%, and 43.4%), and optic nerve sheath fenestration (90.5%, 65.2%, 49.3%, 2.2%, and 9.4%). Authors regard sinus stenting as first-line treatment (Kalyvas, 2021).

A systematic review/meta-analysis of 24 studies (n = 473) of patients with idiopathic intracranial hypertension followed patients for an average of 18.9 months after venous sinus stenting. Authors documented rates of stent survival (84%) and stent-adjacent stenosis (14%). Authors encouraged more study to identify causes of both stenosis and stent failure (Saber, 2018).

A meta-analysis of 29 studies (n = 410) assessed outcomes of patients who underwent dural venous sinus stenting for refractive idiopathic intracranial hypertension, noting stenting is an accepted treatment, but “there are no randomized controlled studies” on outcomes and complications. Technical success was 99.5%, the rate of major complication rate was 1.5%, and repeated procedure occurred in 10% of cases (Leishangthem, 2019).

A systematic review/meta-analysis of 20 studies (n = 474) of intracranial venous sinus stenting for idiopathic intracranial hypertension included 88% females with a mean age of 35 and a mean mass body index of 35 kg/m<sup>2</sup>, who were followed for a median of 18 months after treatment. The review reports rates of papilloedema improvement (93.7%), headache improvement/resolution (79.6%), pulsatile tinnitus resolution (90.3%). The rate of symptom recurrence was 9.8%, and major complications occurred in 1.9% of patients (Nicholson, 2019).

A meta-analysis compared outcomes for optic nerve sheath fenestration (n = 712), diversion of cerebrospinal fluid (n = 435), and dural venous sinus stenting (n = 136) for treating refractory idiopathic intracranial hypertension. Stenting, compared with fenestration and fluid diversion, had superior outcomes for improving vision (78%, versus 59% and 54%); headache (83% versus 44% and 80%); and papilledema (97% versus 80% and 70%). Stenting also had lower rates of major complications (2.9% versus 1.5% and 7.6%) and minor complications (4.4% versus 16.4% and 32.9%). Authors note the paradigm of using cerebrospinal fluid diversion as first-line surgery “may need to be re-examined” (Satti, 2015).

A review of 41 studies (n = 728), including 36 case series and five case reports, compared efficacy of surgical treatments for idiopathic intracranial hypertension, including venous sinus stenting (n = 155). Stenting had satisfactory results in vision and headache improvement, the best complication profile, and a low relapse rate, but with longer follow-up required. No surgical modality was clearly superior. Authors state that stenting as a first-line treatment “may need to be re-examined,” a conclusion opposite that reached by Satti et al. two years earlier (Kalyvas, 2017).

A 2015 Cochrane review reviewed all randomized trials of treatment for idiopathic intracranial hypertension. No such randomized trials existed for stenting; the only two trials in the review addressed treatment with the drug acetazolamide (Piper, 2015).

## References

On April 15, 2021, we searched PubMed and the databases of the Cochrane Library, the U.K. National Health  
CCP.1493

Services Centre for Reviews and Dissemination, the Agency for Healthcare Research and Quality, and the Centers for Medicare & Medicaid Services. Search terms were “idiopathic intracranial hypertension,” “pseudotumor cerebri,” and “stent.” We included the best available evidence according to established evidence

hierarchies (typically systematic reviews, meta-analyses, and full economic analyses, where available) and professional guidelines based on such evidence and clinical expertise.

Al-Mufti F, Dodson V, Amuluri K, et al. Neuroendovascular cerebral sinus stenting in idiopathic intracranial hypertension. *Interv Neurol*. 2020;8(2-6):164-171. Doi: 10.1159/000500051.

Centers for Medicare & Medicaid Services. Endovenous stenting. Local Coverage Determinations L37893, L38231. <https://www.cms.gov/medicare-coverage-database/details/lcd-details.aspx?lcdid=38231&ver=19&keyword=intracranial%20hypertension&keywordType=starts&areald=all&dctype=NCA,CAL,NCD,MEDCAC,TA,MCD,6,3,5,1,F,P&contractOption=all&sortBy=relevance&bc=AAAAAAQAAAA&KeyWordLookUp=Doc&KeyWordSearchType=Exact>. Effective December 27, 2020.

Daggubati LC, Liu KC. Intracranial venous sinus stenting: A review of idiopathic intracranial hypertension and expanding indications. *Cureus*. 2019;11(2):e4008. Doi: 10.7759/cureus.4008.

Hoffmann J, Mollan SP, Paemeleire K et al. European Headache Federation guideline on idiopathic intracranial hypertension. *J Headache Pain*. 2018;19(1):93. Doi: 10.1186/s10194-018-0919-2

Jensen RH, Radojicic A, Yri H. The diagnosis and management of idiopathic intracranial hypertension and the associated headache. *Ther Adv Neurol Disord*. 2016;9(4):317-326. Doi: 10.1177/1756285616635987.

Kalyvas AV, Hughes M, Koutsarmakis C, et al. Efficacy, complications, and cost of surgical interventions for idiopathic intracranial hypertension: A systematic review of the literature. *Acta Neurochir (Wien)*. 2017;159(1):33-49. Doi: 10.1007/s00701-016-3010-2.

Kalyvas A, Neromyliotis E, Koutsamakes C, et al. A systematic review of surgical treatments of idiopathic intracranial hypertension (IIH). *Neurosurg Rev*. 2021;44(2):773-792. Doi: 10.1007/s10143-020-01288-1.

Leishangthem L, SirDeshpande P, Dua D, Satti SR. Dural venous sinus stenting for idiopathic intracranial hypertension: An updated review. *J Neuroradiol*. 2019;46(2):148-154. Doi: 10.1016/j.neurad.2018.09.001.

Mollan SP, Davies B, Silver NC, et al. Idiopathic intracranial hypertension: Consensus guidelines on management. *J Neurol Neurosurg Psychiatry*. 2018;89:1088-1100. Doi: 10.1136/jnnp-2017-317440.

Nicholson P, Brinjikji W, Radovanovic I, et al. Venous sinus stenting for idiopathic intracranial hypertension: A systematic review and meta-analysis. *J Neurointerv Surg*. 2019;11(4):380-385. Doi: 10.1136/neurintsurg-2018-014172.

Piper RJ, Kalyvas AV, Young AMH, Hughes MA, Jamioom AAB, Fouvas IP. Interventions for idiopathic intracranial hypertension. *Cochrane Database Syst Rev*. 2015 Aug 7;2015(8):CD003434. Doi: 10.1002/14651858.CD003434.pub3.

Saber H, Lewis W, Sadeghi M, Rajah G, Narayanan S. Stent survival and stent-adjacent stenosis rates following CCP.1493

venous sinus stenting for idiopathic intracranial hypertension: A systematic review and meta-analysis. *Interv Neurol.* 2018;7(6):490-500. Doi: 10.1159/000490578.

Satti SR, Leishangthem L, Chaudry MI. Meta-analysis of CSF diversion procedures and dural venous sinus stenting in the setting of medically refractory idiopathic intracranial hypertension. *AJNR Am J Neuroradiol*. 2015;36(10):1899-1904. Doi: 10.3174/ajnr.A4377.

Thurtell MJ, Kawasaki A. Update in the management of idiopathic intracranial hypertension. *Neurol Clin*. 2021;39(1):147-161. Doi: 10.1016/j.ncl.2020.09.008.

Wakerley BR, Mollan SP, Sinclair AJ. Idiopathic intracranial hypertension: Update on diagnosis and management. *Clin Med (Lond)*. 2020;20(4):384-388. Doi: 10.7861/clinmed.2020-0232.

Wall M. Idiopathic intracranial hypertension. *Neurol Clin*. 2010;28(3):593-617. Doi: 10.1016/j.ncl.2010.03.003.

Weiner G. Managing Idiopathic Intracranial Hypertension: The Evidence Builds. American Academy of Ophthalmology, Eye Net Magazine. <https://www.aao.org/eyenet/article/managing-idiopathic-intracranial-hypertension-evid>. Published 2021.

## Policy updates

7/2021: initial review date and clinical policy effective date: 8/2021